NPM1 and acute myeloid leukemia: This feature, combined with the low HLA-DR [8], strong CD33 expression [9] and presence of abnormal PML bodies [10], is reminiscent of acute promyelocytic leukemia (APL) and have inspired APL-like treatment strategies (i.e., all-trans retinoic acid and arsenic trioxide) also in NPM1-mutated AML both preclinically [10] and in patients (NCT04689815, NCT03031249).